Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 250 versus ISOVUE M 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 250 versus ISOVUE M 200.
ISOVUE-250 vs ISOVUE-M 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby providing contrast enhancement in imaging studies. Its mechanism of action is physical rather than pharmacological, as it does not have inherent biological activity.
Iodinated radiocontrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during imaging procedures.
Intravenous administration of 50-150 mL (12-37 g iodine) for CT imaging; intra-arterial administration of 10-80 mL (2.5-20 g iodine) for angiography; dose depends on procedure and patient weight.
Intrathecal: 8-12 mL (200 mg Iodine/mL) for lumbar myelography. Intravenous: 50-200 mL for contrast enhancement, administered as a bolus or infusion per procedure.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (normal renal function); clinically, half-life prolonged in renal impairment
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. Prolonged in renal impairment, which may necessitate dose adjustment.
Primarily renal: 90-95% unchanged in urine within 24 hours; biliary/fecal: <5%
Primarily renal: >90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 1% is excreted via biliary/fecal routes.
Category C
Category C
Contrast Media
Contrast Media